Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic Patients

• Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer.
• The tool combines digital pathology and genomic sequencing to generate better patient-specific risk estimates for prostate cancer outcomes.
• The integration marks the first externally developed AI pathology algorithm embedded into Tempus’ platform.

Tempus AI (TEM) has announced the clinical launch of the ArteraAI Prostate Test for patients with metastatic hormone-sensitive prostate cancer (mHSPC). 

The test will be integrated into the Tempus platform and made available to urologists and oncologists. It uses artificial intelligence to analyze a patient’s clinical data and biopsy images to estimate the risk of prostate cancer-specific mortality.

AI Pathology Added To TEM Platform

The ArteraAI Prostate Test is the first externally developed digital pathology algorithm to be offered within the Tempus ecosystem. It combines patient clinical information with biopsy image analysis to generate a personalized risk score for prostate cancer outcomes.

The firm stated that the goal is to help close a treatment gap for around 25,000 new metastatic prostate cancer cases diagnosed in the U.S. each year. By combining Tempus’ genomic sequencing data with Artera’s AI pathology insights, doctors can get a more complete view of a patient’s condition.

Clinicians will be able to order the test as an add-on through Tempus’ existing solid tumor testing portfolio across all ordering channels.

Assessing Risk In A Better Way

Artera chief commercial officer Amanda Lowe said the collaboration aims to deliver AI insights in a simple, accessible way across the Tempus system.

Tempus Diagnostics chief commercial officer Laura Elster said the integration will help doctors make more confident treatment decisions. She added that the new workflow allows clinicians to better assess risk and personalize therapy from the start of a patient’s care journey.

What Retail Thinks About TEM Stock

Stocktwits retail sentiment on TEM is ‘bearish.’ It has remained ‘bearish’ over the past 24 hours with no change.

The stock has fallen nearly 26% year-to-date and is currently trading at $45.49, down from its 52-week high of $104.32.

For updates and corrections, email newsroom[at]stocktwits[dot]com.